BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease. The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays. BioPorto A/S was founded in 1917 and is based in Hellerup, Denmark.
Frequently asked questions
What sector does BioPorto (BIOPOR) operate in?
BioPorto belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is BioPorto (BIOPOR) current stock price?
As of the latest data, BioPorto stock price is DKK 1.20, with a previous close of DKK 1.20. BioPorto lost -DKK 0.01 in the last trading session, representing a -0.42% loss.
What is BioPorto (BIOPOR) current market capitalization?
BioPorto market cap is approximately 591.64 million.
What is BioPorto (BIOPOR) Earnings Per Share (EPS)?
The trailing EPS is -DKK 0.15, and the forward EPS is -DKK 0.07.
Does BioPorto (BIOPOR) pay dividends?
No. BioPorto does not pay a dividend.
What is BioPorto (BIOPOR) beta (volatility) score?
BioPorto has a beta of 1.382, suggesting it is more volatile than the market.
